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This article reviews the application of the human airway Calu-3 cell line as a respiratory model for studying the eﬀects of gas
concentrations, exposure time, biophysical stress, and biological agents on human airway epithelial cells. Calu-3 cells are grown
to confluence at an air-liquid interface on permeable supports. To model human respiratory conditions and treatment modalities,
monolayers are placed in an environmental chamber, and exposed to specific levels of oxygen or other therapeutic modalities such
as positive pressure and medications to assess the eﬀect of interventions on inflammatory mediators, immunologic proteins, and
antibacterial outcomes. Monolayer integrity and permeability and cell histology and viability also measure cellular response to
therapeutic interventions. Calu-3 cells exposed to graded oxygen concentrations demonstrate cell dysfunction and inflammation
in a dose-dependent manner. Modeling positive airway pressure reveals that pressure may exert a greater injurious eﬀect and
cytokine response than oxygen. In experiments with pharmacological agents, Lucinactant is protective of Calu-3 cells compared
with Beractant and control, and perfluorocarbons also protect against hyperoxia-induced airway epithelial cell injury. The Calu-3
cell preparation is a sensitive and eﬃcient preclinical model to study human respiratory processes and diseases related to oxygen-
and ventilator-induced lung injury.
1. Introduction
The airway epithelial is involved in the pathogenesis and
treatment of many lung diseases, including adult and neona-
tal respiratory distress syndrome (RDS), chronic obstructive
pulmonary disease (COPD), asthma, the adverse eﬀects of
positive pressure mechanical ventilation [1–4], and sup-
plemental oxygen therapy [5]. The airway epithelium is
directly exposed to the external environment and is highly
responsive to biophysical and biological stimuli. Via a
variety of cellular pathways and mechanisms, the respiratory
epithelium responds to exogenous substances, stresses, or
medical therapies that may promote airway repair or injury.
Understanding the role of the airway epithelium and
its response to injurious stimuli, therapeutic drugs, and
interventions will aid in determining the mechanisms of
airway injury and should facilitate the development of novel
therapies for lung diseases. This experimental approach is
one component of a robust approach to assess multiple
aspects of respiratory pathophysiology. With the inherent
diﬃculties of primary human lung cell culture and the limit
of whole-animal studies, in vitro models have been developed
to study the mechanism of hyperoxia or positive pressure-
induced lung injury and to evaluate any new therapies [6, 7].
Although numerous in vitro models have been explored
to study the airway epithelium response, we have focused
2 Critical Care Research and Practice
on the Calu-3 cell line for the following reasons. (1) The
Calu-3 cell line (American Type Culture Collection, ATCC
HTB-55) is a well-diﬀerentiated and characterized cell line,
that is derived from human bronchial submucosal glands
[8]. In the human lung, the submucosal glands are a
major source of airway surface liquid, mucins, and other
immunologically active substances, and Calu-3 cells reflect
these properties [9–12]. By contrast, other pulmonary cell
types, such as airway columnar cells and type II (alveolar)
pneumocytes, are relatively less active from a secretory
standpoint and have less impact on the composition of
airway surface liquid. (2) Calu-3 cells are grown at an air-
liquid interface and demonstrate many characteristics of
the bronchiolar epithelium, which, in vivo, serves as the
barrier layer between inspired gas and other visceral tissues.
This attribute is particularly advantageous for the evaluation
of airway injury and response to medical treatments and
respiratory therapeutic interventions. Air-liquid interface
culture enables the approximation of the in vivo situation
of mechanical ventilation and oxygen toxicity better than
other in vitro models [13], such as those using lung explants
or submerged primary cell culture systems. Calu-3 cells
have been used for drug delivery [14], pulmonary drug
disposition [7], and bacterial invasiveness studies [15]. Devor
et al. have employed the Calu-3 cell line as a model system to
study the mechanisms of HCO3
− and Cl− secretion, which
reflects the transport properties of native submucosal gland
serous cells [16].
We have developed a sensitive and eﬃcient model using
Calu-3 cells cultured in an environmental chamber as a respi-
ratory model to study the eﬀects of oxygen concentration and
exposure time [5], biophysical stresses, and biological agents
[10, 12, 13], such as perfluorocarbons (PFC) and surfactant.
PFC is known to exert numerous eﬀects in vitro and in
vivo. Partial liquid ventilation with PFC attenuates oxidative
injury in experimental models of lung injury [17, 18]. PFC
liquid also attenuates oxidative damage to both biologic (rat
endothelial cells) and nonbiologic (linoleic acid in sodium
dodecyl sulfate micelles) systems [19]. Surfactant-associated
proteins play an important role in the maintenance of pul-
monary homeostasis. The deficiency of surfactant-associated
proteins is associated with severe respiratory distress, and,
in the case of surfactant protein B (SP-B), is incompatible
with life [20]. Sinulpeptide (KL-4), a synthetic peptide
that functionally mimics SP-B [21], prevents hyperoxic and
lipopolysaccharide-induced lung injury in mice [22]. An ani-
mal study demonstrated inflammation and lung function in
adult mice with SP-B deficiency and reversal of inflammation
and maintenance of lung function with SP-B administration
in vivo [23].
Apical fluid and protein secretions in Calu-3 cultures are
similar to those from primary airway cultures and model
many aspects of the intraluminal condition in the conducting
airways of the lung. This model allows for the analysis
of airway tissue tolerance of oxygen exposure without the
confounding variables of a whole-animal model.
In these in vitro experiments, clinically relevant outcomes
were measured to assess the eﬀect of respiratory interven-
tions. Since airway inflammation is commonly a result of
barotrauma and oxygen toxicity, ELISA techniques detect
changes in the proinflammatory cytokines IL-6 and IL-8.
Pulmonary edema also results from airway injury, and, to
model this outcome, total protein is measured in the apical
wash fluid. Similarly, Calu-3 monolayer integrity and cellular
physiology are assessed by measuring changes in transep-
ithelial electrical resistance (TER). In previous studies, we
found that TER correlates with FITC dextran flux from
the basolateral to the apical aspect of the monolayer [24].
Finally, histological outcomes are assessed semiquantitatively
by individual cell and monolayer morphology, as well as by
quantifying cell viability.
This article introduces specific experimental methods
for inducing environmental changes on Calu-3 cells, which
are similar to clinical interventions practiced in respiratory
management. In this regard, the methods discussed enable
the study of changes in environment, gas concentrations,
biophysical stresses, and therapeutic interventions on airway
epithelial cells as a function of time and treatment.
2. Materials and Methods
2.1. Calu-3 Cell Culture. Calu-3 cell culture techniques are
well described elsewhere [5, 12, 13]. The cells used for the
experiments were 5–10 passages.
2.2. Collection of Calu-3 Apical Surface Fluid Washings.
Apical surface fluid washings are the source of biologically
active substances secreted apically by Calu-3 cells, and this
fluid is used to model the airway compartment of the lung.
A sample of the Calu-3 apical surface fluid (ASF) is collected
from each transwell insert for each experimental condition
so that the response of individual monolayers is assayed.
Experiments are designed so that each monolayer is used
only once. Therefore, it is necessary to use multiple plates
over the course of each experiment. For example, if the
response of Calu-3 monolayers to a specific concentration of
oxygen is assayed over a 48-hour period, three plates are used.
The first plate is used for the control condition, the second
for 24-hour outcomes, and the third for outcomes at 48
hours.
ASF from Calu-3 cells is collected in the following
fashion [5, 12]. The apical surface of the monolayer is gently
washed twice with 140 μL of sterile normal saline. Washes are
combined for a total of 280 μL for each individual monolayer
per sample. Samples are centrifuged for 15 minutes at
13,000 rcf and at 4◦C, and the supernatants stored in aliquots
at −70◦C for subsequent analysis. The levels of IL-6 and
IL-8 in Calu-3 ASF were measured with quantitative ELISA
using human IL-6 and IL-8 Quantikine ELISA kits (R &
D Systems, Minneapolis, MN). Calu-3 ASF washings used
in the assay were appropriately diluted. All standards and
samples were assayed in duplicate. The test sensitivity for
respective immunoassays was as follows: IL-6 (0.039 pg/mL)
and IL-8 (10 pg/mL). Interassay and intraassay coeﬃcients of
variance are less than 10%.
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2.3. Histology, Cell Viability, and Cytomorphology of Calu-
3 Cells. After exposing Calu-3 monolayers to an experi-
mental condition or treatment, Calu-3 cell histology and
viability are assessed. To evaluate Calu-3 monolayers in situ,
transwell inserts containing Calu-3 monolayers are fixed
in 4% paraformaldehyde. Following fixation, polycarbonate
filters with the adherent monolayers are separated from the
transwell inserts and embedded in paraﬃn. Cross-sections of
the monolayer/filter samples are sectioned (5 μm thick) and
stained with hematoxylin and eosin (H&E) for histological
analysis (Figure 1(a)).
Cell viability and cytomorphological studies are per-
formed using single cell suspensions (SCS) obtained by
harvesting the cells from transwell filters by trypsinization.
Using 20 μL of the SCS, cell viability is determined using
the Trypan blue-exclusion assay. Cytospin slides are prepared
using an additional 100 μL of the SCS and fixed in formalin
and stained with H&E (Figure 1(b)). Cytomorphology is
evaluated in a semi-quantitative manner as the ratio of
abnormal cells to total cells [5]. Abnormal cells are defined
as cells demonstrating any of the following characteristics:
(1) abnormal cellular appearance, (2) swollen nuclei, (3)
intracellular and nuclear vacuoles, or (4) diﬀuse cytoplasm
and cellular debris [5], or a combination of the four.
2.4. Set-Up of the Modular Incubator Chamber (MIC-101).
To establish specific environmental conditions for the experi-
ments described below, a sterile modular incubator chamber
(MIC-101; Billups-Rothenberg, Del Mar, CA) is used. Cell
culture plates are placed into the chamber, and it is sealed
with Dow Corning high vacuum grease (Dow Corning,
Midland, MI). With the chamber sealed and airtight, it is
ready to be pressurized to a maximum of 2 pounds per square
inch (PSI). To finalize the chamber setup, the appropriate
devices and gas sources with or without a humidifier are
attached to the chamber inlet. A three-way stopcock is used
to attach a pressure gauge, oxygen analyzer, or flow meter to
the outlet of the chamber (Figure 2).
2.5. Oxygen Concentration. Supplemental oxygen admin-
istration is an important component of patient care in
respiratory medicine and is critical to the maintenance
of organ homeostasis and neurological function; however,
oxygen can be toxic to tissues of the lung and airway. The
mechanisms of this toxicity include oxidative injury with
the generation of free radicals and direct disruption of cell
membranes. Strategies to control oxygen concentration and
exposure time are employed clinically as a means to control
airway oxidative injury. In the laboratory, it is possible
to study the thresholds and exposure times that can be
detrimental to airway epithelial cells, and these findings may
provide clinically relevant insights into bedside management.
The eﬀect of oxygen concentration on Calu-3 cell
structure and function is assessed in the following manner
[5]. Calu-3 monolayers that exhibit TER values of at least
1,000 ohm·cm2 are exposed to normoxia (FiO2 = 21%,
FiCO2 = 5%, balance nitrogen) or graded hyperoxia
(FiO2 = 40%, 60%, 80%, FiCO2 = 5%, balance nitrogen)
using the chamber described above. To obtain the desired
oxygen concentration, the inlet and outlet ports of the
chamber are opened and attached to a Servo O2-air 960
mixer (Siemens-Elema, Sweden), a 95% oxygen tank, 5%
CO2, and air balance tank. The blended gas is warmed and
humidified with an MR730 respiratory humidifier (Fisher &
Paykel Healthcare, Laguna Hills, CA). The appropriate gas
concentration is flushed through the airtight chamber for
20 minutes at a flow rate of 3 LPM. The chamber oxygen
level is monitored with an oxygen analyzer (MAXO2) (OM-
25AE: Maxtec, Inc., Salt Lake City, UT). After the chamber is
purged, the gas source is disconnected; the chamber is sealed
and placed into a continuous flow CO2 incubator at 37◦C.
The gas in the chamber and the medium in the plates are
changed every 24 hours by following the same procedure.
2.6. Positive Pressure. Positive pressure support is also a
commonly employed strategy to support respiration in
the face of respiratory failure. Positive pressure may be
fixed (continuous positive pressure) or cycled (intermittent
mandatory ventilation) depending upon the clinical situa-
tion and requirements of the patient. As with oxygen therapy,
positive pressure ventilation can be damaging to the lung
and airways, and strategies to minimize airway injury can be
developed through in vitro modeling. Injury due to positive
pressure can result from pressure, stretch, or both [25, 26],
but, in the current experiments, the stress of pressure was
evaluated independent of stretch.
To model the airway injury due to the eﬀects of
continuous positive airway pressure (CPAP), monolayers are
exposed to the experimental conditions designed to model
continuous positive pressure therapy using the incubator
chamber. The desired gas concentrations are achieved by
following the protocol as described above. The outlet of
the chamber was attached to a Ru¨sch pressure manometer
(Teleflexmedical, Inc., Duluth, GA) to achieve normoxia
(21% FiO2) and hyperoxia (60% FiO2) with and without
+20 cmH2O pressure for 24 or 72 hours. When the manome-
ter reading reached the desired level and the temperature
reading was 37◦C, the inlet and outlet of the chamber were
clamped and disconnected from the gas. The gas in the
chamber and the medium in the plates were changed every
24 hours and the conditions again verified.
2.7. Biological Agents. Calu-3 monolayers grown at an air-
liquid interface can be treated with biologically active and
clinically relevant agents to assess the eﬀects of treatment on
cell function and the responses to oxygen and positive pres-
sure. By varying doses and concentrations, dose-response
relationships can be assessed for specific outcomes. Also, it
is possible to compare the eﬀects of apical (airway side) or
basolateral (blood side) treatment of monolayers and explore
potential diﬀerences between these modes of drug delivery.
As is discussed below and in the results reported later,
our laboratory has evaluated a number of clinically relevant
compounds and medications to assess the eﬀect of treatment
on Calu-3 cell responses to various stresses. The agent of
interest is layered onto the apical surface of the monolayer.
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Figure 1: Representative normal morphology of Calu-3 cells. The sections of monolayer (a) and cytospins of Calu-3 cells (b) were stained
with hematoxylin and eosin (n = 6 for each condition). All slides were examined by light microscopy at 40x magnification.
Gas
Apical surface
Membrane filter
Basolateral medium
Cells
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Figure 2: Calu-3 air-liquid interface cell culture in an environmental chamber. Calu-3 cell monolayers were grown at an air-liquid interface
to full confluence before exposure to oxygen, positive pressure, and biological agents. Modular incubator chamber shown on the right;
transwell inserts shown on the left.
2.8. Perfluorochemicals. Mature Calu-3 monolayers treated
with perfluorochemical liquid perflubron (PFB) were
exposed to normoxic (FiO2 = 21%, FiCO2 = 5%, balance
nitrogen) or hyperoxic (FiO2 = 95%, FiCO2 = 5%, balance
nitrogen) conditions.
2.9. Surfactants. Calu-3 cell monolayers cultured at an air-
liquid interface were treated apically with 140 μL of normal
saline, Lucinactant (Surfaxin; Discovery Laboratories, Inc.),
or Beractant (Survanta; Abbott Laboratories, Inc.). Treated
monolayers were exposed to normoxic (FiO2 = 21%,
FiCO2 = 5%, balance nitrogen) or hyperoxic (FiO2 = 60%,
FiCO2 = 5%, balance nitrogen) conditions using a modular
environmental chamber for 24 or 72 hours in an incubator at
37◦C.
2.10. Statistical Analysis. The experimental design used was
an independent group method in which each experiment was
performed on a unique monolayer. At least 6 samples were
used for each group. Statistical analysis was performed using
Statistical Package for the Social Sciences (SPSS, version 17)
software. All data are expressed as mean ± SEM. Diﬀerences
between conditions for each parameter were analyzed using
two-way analyses of variance (ANOVA). Where applicable,
one-way ANOVA were run across groups at each time
interval (i.e., 24 and 72 hrs), and post-hoc analyses were done
using Bonferroni comparisons. Significance was accepted
with P < .05; n = at least 6 monolayers for each condition.
3. Results
3.1. Experiments with Various Concentrations of Oxygen.
Calu-3 cells exposed to graded oxygen concentrations (21%,
40%, 60%, and 80% FiO2) demonstrate cell dysfunction
and inflammation in a dose-dependent manner [5]. TER
decreased in a dose- and time-dependent manner, whereas
cell viability was reduced only at 72 hours and in the 40%,
60%, and 80% FiO2 groups. IL-6 secretion was elevated
in all hyperoxic groups at 24 hours, and both IL-6 and
IL-8 levels were greater in the 40% FiO2 group compared
with all other groups at 72 hours [5]. In this model,
airway epithelial cells demonstrated profound concentration
and time-dependent responses to hyperoxic exposure with
respect to cell physiology, viability, histology, and secretion
of inflammatory mediators.
3.2. Experiments with the Administration of Pressure. Expo-
sure to 21% FiO2 resulted in no changes in Calu-3 cell
structure or function. In the presence of +20 cmH2O pres-
sure for 24 or 72 hours, cell viability decreased in both
pressure-exposed groups (P < .001) but not in the control
and hyperoxia only groups, which were not diﬀerent from
each other at 24 hours (P > .05). By 72 hours, cell viability
was diﬀerent in all groups, in which the hyperoxia-exposed
group was less than the control group (P < .05) and greater
than both pressure-exposed groups (P < .001) (Figure 3). In
Figure 4, transepithelial resistance (TER) was less than in the
control group in all treated groups (P < .001). At 72 hours,
Critical Care Research and Practice 5
70
75
80
85
90
95
100
C
el
lv
ia
bi
lit
y
(%
)
24 72
(hours)
21% FiO2 + 0 cmH2O
60% FiO2 + 0 cmH2O
21% FiO2 − 20 cmH2O
60% FiO2 − 20 cmH2O
∗#
∗#
∗
∗
∗
Figure 3: Cell viability for Calu-3 monolayers exposed to normoxia
or hyperoxia with or without +20 cmH2O pressure. Cell viability
decreased in both pressure-exposed groups (P < .001) but not in the
control and hyperoxia only groups, which were not diﬀerent from
each other at 24 hrs (P > .05). By 72 hrs, cell viability was diﬀerent in
all groups, in which hyperoxia-exposed group was less than control
group (P < .05) and greater than both pressure-exposed groups
(P < .001). Data are mean±SEM; ∗diﬀerent from all other groups at
the same time point; #less than control and hyperoxia groups (n = 6
for each condition).
TER for the hyperoxia-exposed monolayers was less than
that for the other treated groups (P < .001). Similarly, both
IL-6 (Figure 5(a)) and IL-8 (Figure 5(b)) increased in the
pressure-exposed groups over time (P < .001) but not in the
control and hyperoxia alone groups. The pressure-exposed
groups were greater than the control and hyperoxia groups
(P < .001) but not diﬀerent from each other (P > .05).
Cytospin preparations of Calu-3 cells showed normal cellular
histology in the 21% FiO2 group at both time points, whereas
the pressure- and hyperoxia-exposed groups showed more
swollen nuclei and intracellular vacuoles (Figure 6).
3.3. Experiments with Pharmacological Agents. Calu-3
monolayers treated with either normal saline, Lucinactant,
or Beractant were exposed to 60% FiO2 for 24 or 72 hours
[24]. TER and cell viability were greater in both surfactant
groups compared with saline; by 72 hours, Lucinactant cells
had greater TER than Beractant cells. Both surfactant-treated
groups secreted less IL-8 than saline, whereas Lucinactant
cells secreted less IL-6 than both saline and Beractant cells.
Histology indicated less injury with Lucinactant relative
to Beractant and saline. Over 72 hours, Lucinactant was
protective of Calu-3 cells compared with a Beractant and
normal saline control [24].
Calu-3 cells treated with perflubron (PFB) and hyperoxia
showed an increase in TER value, improved histology,
decreased total protein secretion in ASF washings, and
unaltered IL-8 secretion [13]. Cytomorphologic observa-
tions of PFB-treated Calu-3 cells indicated the presence of
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Figure 4: Transepithelial resistance (TER) was less than control in
all treated groups (P < .001), independent of time. At 72 hrs, TER
for the hyperoxia-exposed monolayers was less than that for the
other treated groups (P < .001). Data are mean ± SEM; ∗diﬀerent
from all other groups at the same time point; #less than control at
the same time point (n = 6 for each condition).
varying numbers of diﬀerently sized intracellular vacuoles
during both normoxic and hyperoxic conditions. Calu-3
monolayers exposed to hyperoxia exhibited a loss of cellular
integrity and decreased protein concentration and IL-8
level in ASF washings. In this study, PFB protects against
hyperoxia-induced airway epithelial cell injury by promoting
cellular integrity as well as cytologic modifications [13].
4. Discussion
In this paper, we present our experience using Calu-3 cells
as a model for assessing the eﬀects of oxygen concentration,
positive airway pressure, and several clinically relevant phar-
macological agents on various parameters of lung and airway
injury. Under atmospheric conditions, Calu-3 cells have been
widely used to model lung pathophysiology and therapeu-
tics. Although immortalized, Calu-3 cells are of human
derivation [8] and exhibit many characteristics of primary
airway cultures. Calu-3 cells have been used as a model
to examine transport [6, 27, 28] and metabolism of many
therapeutic compounds [29] and particle-cell interaction
studies [30–32]. Finally, studies regarding the absorption,
metabolism, and distribution of inhaled corticosteroids have
been performed with Calu-3 cell monolayers.
In the model of continuous positive airway pressure,
in which Calu-3 monolayers were exposed to normoxia
(control), hyperoxia, pressure (+20 cmH2O), or a combina-
tion of hyperoxia and positive pressure, a group eﬀect for
cell viability revealed that hyperoxia was less detrimental
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Figure 5: proinflammatory cytokines in ASF from normoxia- or hyperoxia-exposed Calu-3 monolayers with or without +20 cmH2O. Both
IL-6 (a) and IL-8 (b) increased in pressure-exposed groups over time (P < .001) but not in control and hyperoxia alone groups. Pressure-
exposed groups are greater than control and hyperoxia (P < .001) but not diﬀerent from each other. Data are mean ± SEM; ∗greater than
control and hyperoxia; #greater than at 24 hrs. n = 6 for each condition.
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Figure 6: Representative histology. Cytospin preparations of Calu-3 cells after exposure to 72 hrs of normoxia or hyperoxia with or without
+20 cmH2O pressure showed more swollen nuclei and intracellular vacuoles for pressure-treated cells than for the control and hyperoxia
alone groups. Normoxia without pressure-exposed cells exhibited normal cellular histology.
than pressure, but both insults in combination are more
detrimental than either independently. At 24 hours, TER
decreased acutely in all treated Calu-3 monolayers, and there
appeared to be at least partial recovery in some groups by
72 hours. In the current experiments, the proinflammatory
mediators IL-6 and IL-8 secretion increased over time for
up to 72 hours for pressure groups. We can speculate that
positive pressure triggered airway epithelial cells to secrete
more proinflammatory mediators than hyperoxia alone,
and the combination of positive pressure and hyperoxia
did not appear to be additive. The lack of IL-6 and IL-8
secretion in response to hyperoxia was somewhat surprising
but suggests that a higher FiO2 may be required to elicit
a response in this model. Cell morphology of Calu-3 cells
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after exposure to 72 hours of normoxia or hyperoxia with or
without +20 cmH2O pressure showed more swollen nuclei
and intracellular vacuoles for pressure-treated cells than
that for the control and hyperoxia alone groups, whereas
normoxia-exposed cells exhibited normal cellular histology.
These data suggest that Calu-3 monolayers are sensitive to
hyperoxia and positive pressure, but that pressure may exert
a greater injurious eﬀect and cytokine response. These eﬀects
vary with the severity and duration of the stress.
The current studies provide an important complement
to this body of work by expanding the use of Calu-3 cells
to include respiratory interventions commonly employed
in critical care medicine. The experiments show that Calu-
3 cells can be exposed and respond to oxygen, static, and
cyclically delivered positive pressure in clinically relevant
ways. The responses of Calu-3 monolayers, particularly in
terms of the IL-6 and IL-8 responses, reflect those responses
seen in vivo. In addition, these responses can be modulated
with clinically relevant treatments. In our studies, both Luci-
nactant and perflubron attenuated Calu-3 cell responses to
hyperoxia. These findings are notable given the importance
of surfactant replacement therapy in the newborn intensive
care unit and the role of proinflammatory cytokines such
as IL-6 and IL-8 in the pathogenesis of chronic respiratory
disorders such as bronchopulmonary dysplasia.
In summary, Calu-3 air-liquid interface cell culture in an
environmental chamber is a sensitive and eﬃcient model to
simulate clinical situations and for screening respiratory drug
applications. This cell model is useful for the study of human
respiratory diseases, airway injury related to oxygen toxicity,
and positive mechanical ventilation, and the evaluation of
novel therapies. In many cases, isolated cell preparations
allow for very careful control of cell environment (i.e., the
air-liquid interface culture enables the direct sampling and
measurement of luminal airway secretions in the absence
of systemic factors). However, it should be noted that the
absence of systemic inflammation, circulatory factors, and
other paracrine systemic influences is a potential limitation
of the isolated cell system and should be carefully considered
for certain investigations.
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